Search | Clinical Trials Finder

Conditions: HIV, HIV Infections
Interventions: Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 86
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF, EFV/FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 59 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10,577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Foster City, California

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions: ISL, ULO, BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more

Conditions: Human Immunodeficiency Virus
Interventions: bictegravir/emtricitabine/tenofovir alafenamide; Drug
Lead sponsor: Midland Research Group, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Oakland Park, Florida

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, E/C/F/TDF, ATV, RTV, FTC/TDF, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 29
States / cities: Stamford, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 22 more

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more

Conditions: HIV-1 Infection
Interventions: DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 74
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 79
States / cities: Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, COBI, ATV, DRV, NRTI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more

Conditions: HIV Prevention, HIV Infections
Interventions: tenofovir + emtricitabine, lopinavir/ritonavir; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: EVG/COBI/FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Oakland, California • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more

Conditions: HIV-1 Infection, HCV Infection
Interventions: E/C/F/TAF, F/R/TAF, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more

Conditions: HIV Infection
Interventions: FTC/TDF (Truvada®); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 22 Years · Male only
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 56
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 6 more

Conditions: HIV Infections
Interventions: Kaletra + Isentress, Atripla; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 3 more

Conditions: HIV-1 Infection
Interventions: B/F/TAF, NRTIs, Third Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more

Conditions: HIV-1-Infection
Interventions: Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 35
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more

Conditions: HIV-1 Infection
Interventions: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 29
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 25 more

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection